Topics

Valeant Pharmaceuticals International
Allergan reviews meeting requests in takeover bid
Allergan reviews meeting requests in takeover bid

Botox maker Allergan Inc. is reviewing shareholder requests for a special meeting to consider replacing most of its board, a change fellow drugmaker Valeant Pharmaceuticals International Inc. is seeking as part of the hostile takeover attempt it's been waging since April. Allergan has repeatedly rejected Valeant's offers to buy the company, the latest for about $53 billion in cash and stock, saying Valeant is substantially undervaluing the company and that an independent Allergan can generate more value for shareholders. Valeant and its partner — investment fund manager Pershing Square Capital Management LP — said late Friday they had submitted to Allergan written...

Loading